Global Pharmaceutical Contract Manufacturing Market 2024-2028
Pharmaceutical Contract Manufacturing Market 2024-2028
The pharmaceutical contract manufacturing market is forecasted to grow by USD 64.8 bn during 2023-2028, accelerating at a CAGR of 8.1% during the forecast period. The report on the pharmaceutical contract manufacturing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by patent expiry and increasing demand for generic drugs, growing need to focus on core competencies, and strong research funding.
Technavio's pharmaceutical contract manufacturing market is segmented as below:
By End-user
- Big pharmaceutical companies
- Small and medium-sized pharmaceutical companies
- Generic pharmaceutical companies
By Service
- API/bulk drug manufacturing
- Final dosage form
- Secondary packaging
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
This study identifies the increasing number of US fda-approved manufacturing facilities as one of the prime reasons driving the pharmaceutical contract manufacturing market growth during the next few years. Also, rising demand for biological therapies and advent of big data will lead to sizable demand in the market.
The report on the pharmaceutical contract manufacturing market covers the following areas:
- Pharmaceutical contract manufacturing market sizing
- Pharmaceutical contract manufacturing market forecast
- Pharmaceutical contract manufacturing market industry analysis
The vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pharmaceutical contract manufacturing market vendors that include AbbVie Inc., Almac Group Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dalton Pharma Services, DR Reddys Laboratories Ltd., Grifols SA, Laboratory Corp. of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Syneos Health Inc., and Thermo Fisher Scientific Inc.. Also, the pharmaceutical contract manufacturing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.